New Guidance for Hospital Pharmacists on Managing Excreta from Patients Receiving Antibody-Drug Conjugates

A systematic review published on September 12, 2026, provides recommendations for hospital pharmacists regarding the precautionary handling of excreta from patients treated with antibody-drug conjugates (ADCs). The guidance, based on excretion data from various ADCs approved by major regulatory authorities like the FDA and EMA, suggests managing excreta as contaminated for durations ranging from 5 to 144 days post-administration. This highlights the need for improved evidence-based guidance on the safe handling of excreta due to the potential risk of exposure to cytotoxic payloads, emphasizing the role of hospital pharmacists in medication safety and hazardous medicinal product management.